Nuvectis Pharma, Inc. (NVCT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$25.1M
Cash & Equivalents
$6.5M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$578M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase1 Readout | — |
| 2027-03-01 | Phase1 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | PHASE1 | Active Not Recruiting | 45 |
| NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | PHASE1 | Recruiting | 18 |
| NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | PHASE1 | Recruiting | 140 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-23 | 8-K | Nuvectis Pharma, Inc. (NVCT) (CIK 0001875558) - EXHIBIT 99.1 | EDGAR |